ArticleHuman cell2026
HNRNPC contributes to ccRCC progression by stabilizing AURKB mRNA in an m6A-dependent manner.
Article in Human cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study aimed to investigate the expression, biological functions, and underlying mechanisms of HNRNPC in clear cell renal cell carcinoma (ccRCC). The expression of HNRNPC in ccRCC tissues and cell lines was detected. The effects of HNRNPC knockdown and overexpression on ccRCC cell proliferation, migration, and invasion were analyzed using cellular models. The role of HNRNPC in recognizing m6A modifications and regulating AURKB mRNA stability was validated through treatment with the methylation inhibitor STM-245, an actinomycin D stability assay, a dual-luciferase reporter assay, and RNA immunoprecipitation. A nude mouse xenograft model was established for in vivo functional validation. The results showed that HNRNPC was significantly overexpressed in ccRCC tissues and cell lines. Knockdown of HNRNPC suppressed cell proliferation, sphere formation, migration, and invasion, while overexpression promoted these malignant phenotypes. Mechanistically, HNRNPC enhanced the stability and expression of AURKB mRNA by recognizing and binding to m6A modification sites on AURKB mRNA. HNRNPC overexpression reversed the suppression of cellular phenotypes induced by AURKB knockdown. In vivo experiments demonstrated that knockdown of either HNRNPC or AURKB significantly inhibited tumor growth and downregulated Ki-67 expression. In conclusion, HNRNPC contributes malignant progression of ccRCC, at least in part, by recognizing m6A modifications on AURKB mRNA and enhancing its stability, suggesting that the HNRNPC/AURKB axis may serve as a potential therapeutic target for ccRCC.
Indexed as
Identifiers
42690479What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.